Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology_West China Medical Journal

Authors：

ZENG Jinghui ¹ , SONG Kai ¹ , LI Na ¹ , ZHANG Jing ¹ , YANG Longhui ¹ ,  ZHU Ruifang ^1,2

1. School of Nursing, School of Medical Sciences, Shanxi Medical University, Taiyuan, Shanxi 030001, P. R. China;
2. Editorial Department, First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P. R. China;

Corresponding author：

ZHU Ruifang, Email: ruifang.zhu@sxmu.edu.cn

Keywords：

Type 2 diabetes; hypertension; drug food homologous; reverse network pharmacology

DOI：

10.7507/1002-0179.202503136

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To find out Shanxi genuine drug food homologous substances for type 2 diabetes complicated with hypertension, and to explore its mechanism. Methods The targets of type 2 diabetes and hypertension were obtained from TTD, Drugbank and GeneCards databases, and the intersection targets of the two were obtained. After UniProt database transformation, the protein-protein interaction network was established on the String platform. Degree values were used to screen core targets, followed by enrichment analysis. TCMSP database was used to carry out reverse screening of traditional Chinese medicine ingredients and corresponding traditional Chinese medicine. The key target-active ingredient-traditional Chinese medicine network was constructed. Chinese medicine with a certainty value≥3 was overlapped with drug food homology directory, Shanxi genuine drug directory, and drug use law directory of type 2 diabetes complicated with hypertension to obtain the best drug food homologous substances. Results After screening, 715 intersecting targets were identified, 23 key targets and 818 traditional Chinese medicine ingredients were determined, and 24 active ingredients with retention values≥4 were identified as core active ingredients. A total of 302 traditional Chinese medicines were reverse screened. There were 14 kinds of drug food homologous substances, and Radix Astragali was finally selected as the best drug food homologous substance for type 2 diabetes complicated with hypertension. Conclusion Radix Astragali may be used to prevent and treat type 2 diabetes complicated with hypertension, but the related research only involves theoretical aspects, which needs to be verified by trials in the future.

Citation： ZENG Jinghui, SONG Kai, LI Na, ZHANG Jing, YANG Longhui, ZHU Ruifang. Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology. West China Medical Journal, 2026, 41(1): 65-71. doi: 10.7507/1002-0179.202503136 Copy

1.	Bakris G. Similarities and differences between the ACC/AHA and ESH/ESC guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ Res, 2019, 124(7): 969-971.
2.	张洁, 何青芳, 王立新, 等. 浙江省成人高血压合并糖尿病患病率及心血管病风险分析. 预防医学, 2018, 30(2): 109-112.
3.	中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会, 倪青. 糖尿病高血压病证结合诊疗指南. 环球中医药, 2024, 17(1): 173-187.
4.	陈小露, 张耀东, 王立军, 等. 网络药理学在中药治疗糖尿病领域的研究进展. 中药材, 2021, 44(9): 2245-2250.
5.	孙欣缘, 郑雅萍, 孙康萌, 等. 我国食药物质名单梳理、修订与展望. 中国中药杂志, 2025, 50(2): 346-355.
6.	刘晓倩. 基于数据挖掘和网络药理学的中药复方治疗 2 型糖尿病合并高血压用药规律及机制分析. 沈阳: 辽宁中医药大学, 2022.
7.	金恒伊. 基于数据挖掘探讨 2 型糖尿病合并高血压证型特点和用药规律. 沈阳: 辽宁中医药大学, 2024.
8.	李佳蓓, 刘春华, 李洁花, 等. 中医药治疗 2 型糖尿病合并原发性高血压气阴两虚证用药规律探析. 湖南中医杂志, 2023, 39(5): 21-26.
9.	高昆, 林洪源. 山西省道地中药材研究进展. 山西农业科学, 2023, 51(12): 1457-1467.
10.	Martín-Vázquez E, Cobo-Vuilleumier N, López-Noriega L, et al. The PTGS2/COX2-PGE2 signaling cascade in inflammation: pro or anti? A case study with type 1 diabetes mellitus. Int J Biol Sci, 2023, 19(13): 4157-4165.
11.	Guzik TJ, Nosalski R, Maffia P, et al. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol, 2024, 21(6): 396-416.
12.	Barreto-Andrade JN, de Fátima LA, Campello RS, et al. Estrogen receptor 1 (ESR1) enhances Slc2a4/GLUT4 expression by a SP1 cooperative mechanism. Int J Med Sci, 2018, 15(12): 1320-1328.
13.	江顺利. 双酚 A 及其替代物暴露与高血压的关联研究. 武汉: 华中科技大学, 2020.
14.	林智立, 雷蕾, 李长润, 等. 胰岛炎症导致的 2 型糖尿病发病过程的动力学模型及治疗策略. 北京大学学报(自然科学版), 2021, 57(2): 199-208.
15.	Plante TB, Juraschek SP, Howard G, et al. Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension, 2024, 81(6): 1244-1253.
16.	Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res, 2016, 2016: 6809703.
17.	Li WH, Chang ST, Chang SC, et al. Isolation of antibacterial diterpenoids from cryptomeria japonica bark. Nat Prod Res, 2008, 22(12): 1085-1093.
18.	郭胜男, 张莉, 吴深涛, 等. 典型黄酮类化合物改善胰岛素抵抗研究进展. 西部中医药, 2022, 35(11): 144-148.
19.	Muruganathan N, Dhanapal AR, Baskar V, et al. Recent updates on source, biosynthesis, and therapeutic potential of natural flavonoid luteolin: a review. Metabolites, 2022, 12(11): 1145.
20.	杨耀, 陈波, 梁凯伦, 等. 蒙花苷与木犀草素联用对离体血管的舒张作用及其机制研究. 中国中药杂志, 2017, 42(7): 1370-1375.
21.	Qu JT, Zhang DX, Liu F, et al. Vasodilatory effect of wogonin on the rat aorta and its mechanism study. Biol Pharm Bull, 2015, 38(12): 1873-1878.
22.	Lei L, Zhao J, Liu XQ, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways. Drug Des Devel Ther, 2021, 15: 3131-3150.
23.	Chiefari E, Mirabelli M, La Vignera S, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci, 2021, 22(20): 11137.
24.	朱海瑀, 管洪艺, 闫慧新, 等. 中医药通过调控 PI3K/Akt 信号通路防治 2 型糖尿病肝脏胰岛素抵抗的研究进展. 吉林中医药, 2023, 43(11): 1356-1360.
25.	Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci, 2018, 14(11): 1483-1496.
26.	Khalid M, Alkaabi J, Khan MAB, et al. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci, 2021, 22(16): 8590.
27.	黄峰. AGEs-RAGE 在自发性高血压大鼠脑组织的表达及药物干预的研究. 福州: 福建医科大学, 2010.
28.	李琳, 刘瑜, 刘屏, 等. 黄芪多糖对 MIN6 细胞增殖、凋亡及胰岛素分泌的影响. 中国新药杂志, 2011, 20(21): 2139-2142.
29.	陈思羽, 唐思梦, 王颖, 等. 黄芪多糖对 2 型糖尿病模型大鼠餐后 1 h 血糖的影响. 中药新药与临床药理, 2020, 31(4): 396-401.
30.	季天娇. 黄芪甲苷调节 PI3K/Akt 通路来改善 2 型糖尿病大鼠肝糖代谢异常的分子机制. 合肥: 安徽医科大学, 2020.
31.	刘晓睿, 李健. 黄芪有效成分的降压、降脂作用. 中国老年学杂志, 2015, 35(17): 4800-4801.
32.	巩莎, 可海霞. 黄芪甲苷通过抑制氯化物细胞内通道蛋白 4/ADP 核糖基化因子 6 信号通路改善血管紧张素Ⅱ诱导的高血压大鼠模型的心肌损伤. 中华高血压杂志, 2024, 32(1): 43-50.

1. Bakris G. Similarities and differences between the ACC/AHA and ESH/ESC guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults. Circ Res, 2019, 124(7): 969-971.
2. 张洁, 何青芳, 王立新, 等. 浙江省成人高血压合并糖尿病患病率及心血管病风险分析. 预防医学, 2018, 30(2): 109-112.
3. 中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会, 倪青. 糖尿病高血压病证结合诊疗指南. 环球中医药, 2024, 17(1): 173-187.
4. 陈小露, 张耀东, 王立军, 等. 网络药理学在中药治疗糖尿病领域的研究进展. 中药材, 2021, 44(9): 2245-2250.
5. 孙欣缘, 郑雅萍, 孙康萌, 等. 我国食药物质名单梳理、修订与展望. 中国中药杂志, 2025, 50(2): 346-355.
6. 刘晓倩. 基于数据挖掘和网络药理学的中药复方治疗 2 型糖尿病合并高血压用药规律及机制分析. 沈阳: 辽宁中医药大学, 2022.
7. 金恒伊. 基于数据挖掘探讨 2 型糖尿病合并高血压证型特点和用药规律. 沈阳: 辽宁中医药大学, 2024.
8. 李佳蓓, 刘春华, 李洁花, 等. 中医药治疗 2 型糖尿病合并原发性高血压气阴两虚证用药规律探析. 湖南中医杂志, 2023, 39(5): 21-26.
9. 高昆, 林洪源. 山西省道地中药材研究进展. 山西农业科学, 2023, 51(12): 1457-1467.
10. Martín-Vázquez E, Cobo-Vuilleumier N, López-Noriega L, et al. The PTGS2/COX2-PGE2 signaling cascade in inflammation: pro or anti? A case study with type 1 diabetes mellitus. Int J Biol Sci, 2023, 19(13): 4157-4165.
11. Guzik TJ, Nosalski R, Maffia P, et al. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol, 2024, 21(6): 396-416.
12. Barreto-Andrade JN, de Fátima LA, Campello RS, et al. Estrogen receptor 1 (ESR1) enhances Slc2a4/GLUT4 expression by a SP1 cooperative mechanism. Int J Med Sci, 2018, 15(12): 1320-1328.
13. 江顺利. 双酚 A 及其替代物暴露与高血压的关联研究. 武汉: 华中科技大学, 2020.
14. 林智立, 雷蕾, 李长润, 等. 胰岛炎症导致的 2 型糖尿病发病过程的动力学模型及治疗策略. 北京大学学报(自然科学版), 2021, 57(2): 199-208.
15. Plante TB, Juraschek SP, Howard G, et al. Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension, 2024, 81(6): 1244-1253.
16. Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res, 2016, 2016: 6809703.
17. Li WH, Chang ST, Chang SC, et al. Isolation of antibacterial diterpenoids from cryptomeria japonica bark. Nat Prod Res, 2008, 22(12): 1085-1093.
18. 郭胜男, 张莉, 吴深涛, 等. 典型黄酮类化合物改善胰岛素抵抗研究进展. 西部中医药, 2022, 35(11): 144-148.
19. Muruganathan N, Dhanapal AR, Baskar V, et al. Recent updates on source, biosynthesis, and therapeutic potential of natural flavonoid luteolin: a review. Metabolites, 2022, 12(11): 1145.
20. 杨耀, 陈波, 梁凯伦, 等. 蒙花苷与木犀草素联用对离体血管的舒张作用及其机制研究. 中国中药杂志, 2017, 42(7): 1370-1375.
21. Qu JT, Zhang DX, Liu F, et al. Vasodilatory effect of wogonin on the rat aorta and its mechanism study. Biol Pharm Bull, 2015, 38(12): 1873-1878.
22. Lei L, Zhao J, Liu XQ, et al. Wogonin alleviates kidney tubular epithelial injury in diabetic nephropathy by inhibiting PI3K/Akt/NF-κB signaling pathways. Drug Des Devel Ther, 2021, 15: 3131-3150.
23. Chiefari E, Mirabelli M, La Vignera S, et al. Insulin resistance and cancer: in search for a causal link. Int J Mol Sci, 2021, 22(20): 11137.
24. 朱海瑀, 管洪艺, 闫慧新, 等. 中医药通过调控 PI3K/Akt 信号通路防治 2 型糖尿病肝脏胰岛素抵抗的研究进展. 吉林中医药, 2023, 43(11): 1356-1360.
25. Huang X, Liu G, Guo J, et al. The PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci, 2018, 14(11): 1483-1496.
26. Khalid M, Alkaabi J, Khan MAB, et al. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci, 2021, 22(16): 8590.
27. 黄峰. AGEs-RAGE 在自发性高血压大鼠脑组织的表达及药物干预的研究. 福州: 福建医科大学, 2010.
28. 李琳, 刘瑜, 刘屏, 等. 黄芪多糖对 MIN6 细胞增殖、凋亡及胰岛素分泌的影响. 中国新药杂志, 2011, 20(21): 2139-2142.
29. 陈思羽, 唐思梦, 王颖, 等. 黄芪多糖对 2 型糖尿病模型大鼠餐后 1 h 血糖的影响. 中药新药与临床药理, 2020, 31(4): 396-401.
30. 季天娇. 黄芪甲苷调节 PI3K/Akt 通路来改善 2 型糖尿病大鼠肝糖代谢异常的分子机制. 合肥: 安徽医科大学, 2020.
31. 刘晓睿, 李健. 黄芪有效成分的降压、降脂作用. 中国老年学杂志, 2015, 35(17): 4800-4801.
32. 巩莎, 可海霞. 黄芪甲苷通过抑制氯化物细胞内通道蛋白 4/ADP 核糖基化因子 6 信号通路改善血管紧张素Ⅱ诱导的高血压大鼠模型的心肌损伤. 中华高血压杂志, 2024, 32(1): 43-50.

West China Medical Journal

Study on the mechanism of Shanxi genuine drug food homologous substances in preventing type 2 diabetes complicated with hypertension based on reverse network pharmacology

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content